Tatiana Aldaz1, Pasquale Nigro1, Almudena Sánchez-Gómez1, Celia Painous1, Lluís Planellas1, Pilar Santacruz1,2, Ana Cámara1, Yaroslau Compta1,3,4, Francesc Valldeoriola1,3,4, Maria J Martí1,3,4, Esteban Muñoz5,6,7,8. 1. Parkinson's Disease and Movement Disorders Unit, Department of Neurology, Hospital Clinic of Barcelona, Villarroel 170, 08036, Barcelona, Catalonia, Spain. 2. European Huntington's Disease Network (EHDN), Barcelona, Spain. 3. Institut de Neurociències, University of Barcelona, Barcelona, Spain. 4. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. 5. Parkinson's Disease and Movement Disorders Unit, Department of Neurology, Hospital Clinic of Barcelona, Villarroel 170, 08036, Barcelona, Catalonia, Spain. jemunoz@clinic.cat. 6. Institut de Neurociències, University of Barcelona, Barcelona, Spain. jemunoz@clinic.cat. 7. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. jemunoz@clinic.cat. 8. European Huntington's Disease Network (EHDN), Barcelona, Spain. jemunoz@clinic.cat.
Abstract
BACKGROUND/AIMS: The presence of non-motor symptoms in Huntington's disease (HD) has not been systematically assessed so far. Our objective was to know their prevalence and to compare it with a cohort of patients with Parkinson's disease (PD). MATERIALS AND METHODS: Participants were consecutively recruited from our outpatient clinic. They were assessed through the motor part of the Unified Huntington's Disease Rating Scale, the motor part of the Unified Parkinson's Disease Rating Scale, the total functional capacity scale and the PD non-motor symptoms questionnaire. RESULTS: We enrolled 123 participants: 53 HD, 45 PD and 25 healthy controls (HC). Non-motor symptoms were significantly more prevalent in HD patients than in HC. The most frequent non-motor symptoms in HD, involving more than 50% of patients, were attentional deficits, apathy, dysphagia, memory complaints, depression falls, insomnia and urinary urgency. The total score of non-motor symptoms correlated with disease duration, total functional capacity and disease stage. HD scored significantly higher than PD in 11 items (dysphagia, constipation, bowel incontinence, faecal tenesmus, weight loss, memory, apathy, attention, falls, nightmares, delusions) and in four domains (cognitive, hallucinations and delusions, digestive and cardiovascular). PD did not score significantly higher than HD in any domain. CONCLUSIONS: HD patients have a high prevalence of non-motor symptoms, which is even higher than in PD, and correlates with disease progression.
BACKGROUND/AIMS: The presence of non-motor symptoms in Huntington's disease (HD) has not been systematically assessed so far. Our objective was to know their prevalence and to compare it with a cohort of patients with Parkinson's disease (PD). MATERIALS AND METHODS: Participants were consecutively recruited from our outpatient clinic. They were assessed through the motor part of the Unified Huntington's Disease Rating Scale, the motor part of the Unified Parkinson's Disease Rating Scale, the total functional capacity scale and the PD non-motor symptoms questionnaire. RESULTS: We enrolled 123 participants: 53 HD, 45 PD and 25 healthy controls (HC). Non-motor symptoms were significantly more prevalent in HD patients than in HC. The most frequent non-motor symptoms in HD, involving more than 50% of patients, were attentional deficits, apathy, dysphagia, memory complaints, depression falls, insomnia and urinary urgency. The total score of non-motor symptoms correlated with disease duration, total functional capacity and disease stage. HD scored significantly higher than PD in 11 items (dysphagia, constipation, bowel incontinence, faecal tenesmus, weight loss, memory, apathy, attention, falls, nightmares, delusions) and in four domains (cognitive, hallucinations and delusions, digestive and cardiovascular). PD did not score significantly higher than HD in any domain. CONCLUSIONS: HD patients have a high prevalence of non-motor symptoms, which is even higher than in PD, and correlates with disease progression.
Authors: Kallol Ray Chaudhuri; Pablo Martinez-Martin; Anthony H V Schapira; Fabrizio Stocchi; Kapil Sethi; Per Odin; Richard G Brown; William Koller; Paolo Barone; Graeme MacPhee; Linda Kelly; Martin Rabey; Doug MacMahon; Sue Thomas; William Ondo; David Rye; Alison Forbes; Susanne Tluk; Vandana Dhawan; Annette Bowron; Adrian J Williams; Charles W Olanow Journal: Mov Disord Date: 2006-07 Impact factor: 10.338
Authors: Jorien M M van der Burg; Annika Winqvist; N Ahmad Aziz; Marion L C Maat-Schieman; Raymund A C Roos; Gillian P Bates; Patrik Brundin; Maria Björkqvist; Nils Wierup Journal: Neurobiol Dis Date: 2011-05-23 Impact factor: 5.996
Authors: J Andrich; T Schmitz; C Saft; T Postert; P Kraus; J T Epplen; H Przuntek; M W Agelink Journal: J Neurol Neurosurg Psychiatry Date: 2002-06 Impact factor: 10.154
Authors: Sven H Stüwe; Oliver Goetze; Carsten Lukas; Peter Klotz; Rainer Hoffmann; Matthias Banasch; Michael Orth; Wolfgang E Schmidt; Ralf Gold; Carsten Saft Journal: Neurology Date: 2013-02-06 Impact factor: 9.910
Authors: Iris van der Lijn; Gera A de Haan; Famke Huizinga; Fleur E van der Feen; A Wijnand F Rutgers; Catherina Stellingwerf; Teus van Laar; Joost Heutink Journal: J Parkinsons Dis Date: 2022 Impact factor: 5.520
Authors: Daniel Zielonka; Grzegorz Witkowski; Elzbieta A Puch; Marta Lesniczak; Iwona Mazur-Michalek; Mark Isalan; Michal Mielcarek Journal: Front Med (Lausanne) Date: 2020-03-11